Clinical Roundup Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows January 10, 2025Vol.51 No.01
Clinical Roundup Elinzanetant meets all endpoints in phase III trial for vasomotor symptoms caused by breast cancer treatments January 10, 2025Vol.51 No.01
Clinical Roundup Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows January 10, 2025Vol.51 No.01
Clinical Roundup Heart disease patients may face increased breast cancer risk, MD Anderson observational study finds January 10, 2025Vol.51 No.01
Clinical Roundup Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show December 13, 2024Vol.50 No.46
Clinical Roundup Imlunestrant improves PFS in breast cancer, phase III data show December 13, 2024Vol.50 No.46
Clinical Roundup AI test is equivalent to Oncotype DX at predicting breast cancer recurrence, study shows December 13, 2024Vol.50 No.46
Clinical Roundup MammaPrint test demonstrates utility in predicting chemotherapy benefit over five years December 13, 2024Vol.50 No.46
Clinical Roundup Genetic disposition increases the risk of breast cancer metastasis December 13, 2024Vol.50 No.46
Clinical Roundup Kisqali shows reduction in distant recurrence in early breast cancer, phase III data show December 13, 2024Vol.50 No.46
